In addition to being present on HSCs, CD33 is also present on hepatic Kupffer cells, which raises the risk of life threatening veno-occlusive disease which has been observed after treatment with gemtuzumab ozogamicin, a monoclonal antibody-drug conjugate against CD33 [23]. Here, CD33 is linked to hepatic veno-occlusive disease.